NASDAQ · Biotechnology

Aktis Oncology, Inc. (AKTS) Stock

$23.73 +4.77% NASDAQ: AKTS Healthcare

Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment.

Valuation

MetricValue
Price$23.73
Market Cap$1.27B
P/E Ratio-38.90
P/B Ratio2.59
P/S Ratio248.63
EPS (TTM)$-1.81
52-Week High$34.19
52-Week Low$14.72
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-44.11%
ROA-5.80%
ROCE-7.30%
Gross Margin87.21%
Operating Margin-786.36%
Net Margin-656.52%
Debt/Equity0.02
Current Ratio19.49

Annual Financials (USD)

Metric2022202320242025
Revenue$0$0$1.0M$6.0M
Operating Profit$-20.0M$-35.0M$-52.0M$-75.0M
Net Profit$-18.0M$-29.0M$-44.0M$-64.0M
EPS$-0.51$-0.82$-1.26$-1.19
Op Margin——-3500.3%-1149.5%

Balance Sheet (USD)

Metric2022202320242025
Total Assets$138.0M$122.0M$326.0M$265.0M
Total Liabilities$158.0M$169.0M$414.0M$411.0M
Cash$129.0M$30.0M$37.0M$38.0M
Borrowings$2.0M$13.0M$12.0M$12.0M

Latest News

Aktis Oncology Insider Sold Shares Worth $1,387,558, According to a Recent SEC Filing MT Newswires · Jul 10, 2026 Aktis Oncology Insider Sold Shares Worth $1,388,701, According to a Recent SEC Filing MT Newswires · Jul 10, 2026 Raymond James Initiates Aktis Oncology at Strong Buy With $40 Price Target MT Newswires · Jun 16, 2026 Aktis Oncology to Present at the Jefferies Global Healthcare Conference GlobeNewswire · May 27, 2026 A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound Simply Wall St. · May 25, 2026

Cash Flow (USD)

Metric2022202320242025
Operating Cash Flow$-18.0M$-30.0M$15.0M$-64.0M
Investing Cash Flow$-5.0M$-73.0M$-193.0M$56.0M
Financing Cash Flow$0$0$-2.0M$-2.0M
Net Cash Flow$100.0M$-99.0M$8.0M$1.0M
Free Cash Flow$-20.0M$-34.0M$12.0M$-74.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.40
EV / EBITDA-28.86
FCF Yield-3.53%
Quick Ratio19.49
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held14.14%
Institutions Held74.41%
Institutions Float Held86.67%
Institutional HolderSharesReport Date
MPM Bioimpact LLC4,835,8722026-03-31
EcoR1 Capital, LLC4,824,4692026-03-31
Blue Owl Capital Holdings LP3,161,3482026-03-31
Wellington Management Group, LLP2,317,0442026-03-31
T. Rowe Price Investment Management, Inc.2,123,8122026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Aktis Oncology, Inc.

Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.

Aktis Oncology, Inc. is led by CEO Matthew Roden, employs 79 people, headquartered in US, publicly traded since 2026.

Aktis Oncology, Inc. (AKTS) stock trades at $23.73 with a market capitalization of $1.27B. The stock is valued at a price-to-earnings (P/E) ratio of -38.90, price-to-book of 2.59, price-to-sales of 248.63. Over the past 52 weeks the stock has ranged between $14.72 and $34.19, and currently trades 30.6% below its 52-week high.

On profitability, Aktis Oncology, Inc. generates a return on equity (ROE) of -44.11%, return on capital employed of -7.30%, an operating margin of -786.36%, a net profit margin of -656.52%.

Official website: www.aktisoncology.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides